Zolimomab aritox
Zolimomab aritox is a mouse monoclonal antibody which has been investigated for the treatment of systemic lupus erythematosus[1] and graft-versus-host disease,[2] but the studies failed to show positive effects of the drug.
| Monoclonal antibody | |
|---|---|
| Type | Whole antibody |
| Source | Mouse |
| Target | CD5 |
| Clinical data | |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
| KEGG | |
  (what is this?) (verify) | |
It is an anti-CD5 antibody which is linked to the A chain of the ricin protein (which is reflected by the aritox in the drug's name).[3]
See also
References
- Stafford FJ, Fleisher TA, Lee G, Brown M, Strand V, Austin HA, et al. (November 1994). "A pilot study of anti-CD5 ricin A chain immunoconjugate in systemic lupus erythematosus". The Journal of Rheumatology. 21 (11): 2068–70. PMID 7532717.
- Przepiorka D, LeMaistre CF, Huh YO, Luna M, Saria EA, Brown CT, Champlin RE (April 1994). "Evaluation of anti-CD5 ricin A chain immunoconjugate for prevention of acute graft-vs.-host disease after HLA-identical marrow transplantation". Therapeutic Immunology. 1 (2): 77–82. PMID 7584486.
- "Recommended Inn List 41 International Nonproprietary Names for Pharmaceutical Substances" (PDF). WHO Drug Information. 13 (1): 56. 1999. Archived from the original (PDF) on February 23, 2012.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.